(3R,6R)-6-<(benzyloxycarbonyl)amino>-3-phenylperhydro-1,4-thiazepin-5-one | 110143-63-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3R,6R)-6-<(benzyloxycarbonyl)amino>-3-phenylperhydro-1,4-thiazepin-5-one
• 英文别名: (3R-cis)-tetrahydro-3-phenyl-6-[[(phenylmethoxy)carbonyl]amino]-1,4-thiazepin-5(4H)-one；benzyl N-[(3R,6R)-5-oxo-3-phenyl-1,4-thiazepan-6-yl]carbamate
• CAS: 110143-63-0
• 化学式: C₁₉H₂₀N₂O₃S
• 分子量: 356.445
• InChiKey: NSKKJFWBQHFRQX-IRXDYDNUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  92.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3R,6R)-6-<(benzyloxycarbonyl)amino>-3-phenylperhydro-1,4-thiazepin-5-one 在 氢溴酸 、 溶剂黄146 作用下， 反应 3.0h， 生成 (3R,6R)-6-amino-3-phenylperhydro-1,4-thiazepin-5-one hydrobromide
  参考文献：
  名称：

  Angiotensin-converting enzyme inhibitors. Perhydro-1,4-thiazepin-5-one derivatives

  摘要：

  alpha-[6-[[(S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-5-oxoperhydro -1,4-thiazepin-4-yl]acetic acids (monoester monoacids) and their dicarboxylic acids having the hydrophobic substituents at the 2- or 3-position of the thiazepinone ring were prepared and assayed for angiotensin-converting enzyme (ACE) inhibitory activity. The dicarboxylic acids having the pseudoequatorial amino groups at the 6-position and the pseudoequatorial hydrophobic substituents at the 2- or 3-position of the chair conformation of the thiazepinone ring had potent in vitro inhibitory activity. The monoester monoacids having the hydrophobic substituents at the 2-position suppressed pressor response to angiotensin I for a longer duration than those having the substituents at the 3-position when administered orally. The structure-activity relationship was studied by conformational energy calculations of the thiazepinone ring.

  DOI：

  10.1021/jm00394a009
• 作为产物：
  描述：

  苄氧羰基半胱氨酸 在 N-甲基吗啉 、 potassium fluoride 、 叠氮磷酸二苯酯 、 苯甲醚 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 (3R,6R)-6-<(benzyloxycarbonyl)amino>-3-phenylperhydro-1,4-thiazepin-5-one
  参考文献：
  名称：

  Angiotensin-converting enzyme inhibitors. Perhydro-1,4-thiazepin-5-one derivatives

  摘要：

  alpha-[6-[[(S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-5-oxoperhydro -1,4-thiazepin-4-yl]acetic acids (monoester monoacids) and their dicarboxylic acids having the hydrophobic substituents at the 2- or 3-position of the thiazepinone ring were prepared and assayed for angiotensin-converting enzyme (ACE) inhibitory activity. The dicarboxylic acids having the pseudoequatorial amino groups at the 6-position and the pseudoequatorial hydrophobic substituents at the 2- or 3-position of the chair conformation of the thiazepinone ring had potent in vitro inhibitory activity. The monoester monoacids having the hydrophobic substituents at the 2-position suppressed pressor response to angiotensin I for a longer duration than those having the substituents at the 3-position when administered orally. The structure-activity relationship was studied by conformational energy calculations of the thiazepinone ring.

  DOI：

  10.1021/jm00394a009

文献信息

• Diazepine containing dual action inhibitors
  申请人：Bristol-Myers Squibb Co.

  公开号：US05646276A1

  公开（公告）日：1997-07-08

  Compounds of the formula ##STR1## wherein X.sub.1 is ##STR2## are disclosed as possessing inhibotory activity against angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) and thus being useful as cardiovascular agents.

  本发明披露了化学式为##STR1##其中X.sub.1为##STR2##的化合物具有抑制血管紧张素转化酶(ACE)和中性内肽酶(NEP)的活性，因此可用作心血管药物。
• Spiro lactam dual action inhibitors
  申请人：Bristol-Myers Squibb

  公开号：US05654294A1

  公开（公告）日：1997-08-05

  Compounds of the formula ##STR1## are disclosed as possessing inhibotory activity against angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) and thus being useful as cardiovascular agents. Processes for preparing these compounds are also disclosed.

  本发明公开了化学式为##STR1##的化合物，具有抑制血管紧张素转化酶（ACE）和中性内肽酶（NEP）的活性，因此可用作心血管药物。本发明还公开了制备这些化合物的方法。
• Dual action inhibitors containing a pyridazinodiazepine or
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US05723602A1

  公开（公告）日：1998-03-03

  Compounds of the formula ##STR1## wherein X.sub.1 is ##STR2## are disclosed. These compounds possess inhibitory activity against angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) and are thus useful as cardiovascular agents.

  本发明揭示了化学式为##STR1##的化合物，其中X.sub.1为##STR2##。这些化合物具有抑制血管紧张素转化酶（ACE）和中性内肽酶（NEP）的活性，因此可用作心血管药物。
• Acylmercaptoalkanoylamino and mercaptoalkanoylamino benzazepines
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US05723457A1

  公开（公告）日：1998-03-03

  Compounds of the formula ##STR1## wherein X.sub.1 is ##STR2## are disclosed. These compounds possess inhibitory activity against angiotensin converting enzyme and neutral endopeptidase and thus are useful as cardiovascular agents.

  本发明揭示了分子式为##STR1##其中X.sub.1为##STR2##的化合物。这些化合物具有抑制血管紧张素转化酶和中性内肽酶的活性，因此可用作心血管药物。
• Processes for preparing azepiones useful as intermediates in the
  申请人：E. R. Squibbs & Sons, Inc.

  公开号：US05856476A1

  公开（公告）日：1999-01-05

  Processes are disclosed for preparing the azepine intermediates of the formula ##STR1## These intermediates can be reacted with acylmercaptocarboxylic acids of the formula ##STR2## to give the pharmaceutically active products.

  本发明揭示了制备公式 ##STR1## 的氮杂环中间体的过程。这些中间体可以与公式 ##STR2## 的酰基巯基羧酸反应，从而得到具有药用活性的产物。